These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34543853)

  • 21. Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood.
    Matikainen-Ankney BA; Kezunovic N; Menard C; Flanigan ME; Zhong Y; Russo SJ; Benson DL; Huntley GW
    J Neurosci; 2018 Nov; 38(45):9700-9711. PubMed ID: 30249796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
    Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
    Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LRRK2 impairs autophagy by mediating phosphorylation of leucyl-tRNA synthetase.
    Ho DH; Kim H; Nam D; Sim H; Kim J; Kim HG; Son I; Seol W
    Cell Biochem Funct; 2018 Dec; 36(8):431-442. PubMed ID: 30411383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human LRRK2 G2019S mutation represses post-synaptic protein PSD95 and causes cognitive impairment in transgenic mice.
    Adeosun SO; Hou X; Zheng B; Melrose HL; Mosley T; Wang JM
    Neurobiol Learn Mem; 2017 Jul; 142(Pt B):182-189. PubMed ID: 28487191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluctuation Imaging of LRRK2 Reveals that the G2019S Mutation Alters Spatial and Membrane Dynamics.
    Sanstrum BJ; Goo BMSS; Holden DZY; Delgado DD; Nguyen TPN; Lee KD; James NG
    Molecules; 2020 May; 25(11):. PubMed ID: 32486414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A.
    Rivero-Ríos P; Romo-Lozano M; Madero-Pérez J; Thomas AP; Biosa A; Greggio E; Hilfiker S
    J Biol Chem; 2019 Mar; 294(13):4738-4758. PubMed ID: 30709905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy.
    Su YC; Guo X; Qi X
    Biochim Biophys Acta; 2015 Jan; 1852(1):12-21. PubMed ID: 25446991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and neuropathological features of progressive supranuclear palsy in Leucine rich repeat kinase (LRRK2) G2019S mutation carriers.
    Vilas D; Sharp M; Gelpi E; Genís D; Marder KS; Cortes E; Vonsattel JP; Tolosa E; Alcalay RN
    Mov Disord; 2018 Feb; 33(2):335-338. PubMed ID: 29119599
    [No Abstract]   [Full Text] [Related]  

  • 30. G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization.
    Papkovskaia TD; Chau KY; Inesta-Vaquera F; Papkovsky DB; Healy DG; Nishio K; Staddon J; Duchen MR; Hardy J; Schapira AH; Cooper JM
    Hum Mol Genet; 2012 Oct; 21(19):4201-13. PubMed ID: 22736029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
    Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT
    Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
    Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
    J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early-onset pathologically proven multiple system atrophy with LRRK2 G2019S mutation.
    Riboldi GM; Palma JA; Cortes E; Iida MA; Sikder T; Henderson B; Raj T; Walker RH; Crary JF; Kaufmann H; Frucht S
    Mov Disord; 2019 Jul; 34(7):1080-1082. PubMed ID: 31077434
    [No Abstract]   [Full Text] [Related]  

  • 35. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LRRK2 G2019S Parkinson's disease with more benign phenotype than idiopathic.
    Ben Romdhan S; Farhat N; Nasri A; Lesage S; Hdiji O; Ben Djebara M; Landoulsi Z; Stevanin G; Brice A; Damak M; Gouider R; Mhiri C
    Acta Neurol Scand; 2018 Nov; 138(5):425-431. PubMed ID: 29989150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.
    Leśniak RK; Nichols RJ; Schonemann M; Zhao J; Gajera CR; Fitch WL; Lam G; Nguyen KC; Smith M; Montine TJ
    Eur J Med Chem; 2022 Feb; 229():114080. PubMed ID: 34992038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts.
    Korecka JA; Thomas R; Christensen DP; Hinrich AJ; Ferrari EJ; Levy SA; Hastings ML; Hallett PJ; Isacson O
    Hum Mol Genet; 2019 Oct; 28(19):3232-3243. PubMed ID: 31261377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine neuron-specific LRRK2 G2019S effects on gene expression revealed by translatome profiling.
    Pallos J; Jeng S; McWeeney S; Martin I
    Neurobiol Dis; 2021 Jul; 155():105390. PubMed ID: 33984508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.